Dyne Therapeutics (DYN) Analyst & Key Data

Analyst Consensus

Buy22 analysts

Buy

Updated Sep 12, 2026

Total Analysts22

Strong Buy

1

Buy

11

Hold

1

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$18.21

Median Target+94.45%

$35.41

Potential upside vs current price

DCF Value-62.99%

$6.74

Potential downside vs current price

Current Stock Price

$18.21

Median Target+94.45%

$35.41

Potential upside vs current price

DCF Value-62.99%

$6.74

Potential downside vs current price

Analyst Consensus

Buy22 analysts

Buy

Updated Sep 12, 2026

Total Analysts22

Strong Buy

1

Buy

11

Hold

1

Sell

1

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score2.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$18.21

Median Target+94.45%

$35.41

Potential upside vs current price

DCF Value-62.99%

$6.74

Potential downside vs current price

Current Stock Price

$18.21

Median Target+94.45%

$35.41

Potential upside vs current price

DCF Value-62.99%

$6.74

Potential downside vs current price

Dyne Therapeutics, Inc.